Company Milestones
Every Step Counts
We are proud of the milestones we have accomplished since our founding in 2016. Each step forward is a step closer to our goal to improve healthcare through better disease detection.
2016
BillionToOne was founded
2017
Rented half of a bench at Start X
September 2018
Received a National Institutes of Health grant for the first single-gene NIPT clinical study with Baylor University
Jan 2019
Moved to the first non-shared lab with six employees
March 2019
BillionToOne Closes $15 Million Series A Funding
June 2019
Achieved Clinical Laboratory Improvement Amendments (CLIA) certification
July 2019
Received the first UNITY commercial sample
October 2019
Published first single-gene NIPT validation study in Nature Scientific Reports
July 2020
Launched UNITY aneuploidy and RhD tests
April 2021
Moved into lab 2.0
June 2021
BillionToOne Closes $55M Series B Funding
March 2022
BillionToOne Closes $125M Series C Funding
April 2022
Published single-gene NIPT health economics study in Journal of Health Economics
April 2022
Hired 200th employee
May 2022
Achieved College of American Pathologists (CAP) Lab Accreditation Program Certification
May 2022
Published single-gene NIPT sickle cell disease data in the American Journal of Hematology
June 2022
Northstar Select and Response launched for research use only (RUO)
September 2022
Launched UNITY fetal antigen NIPT for alloimmunized pregnant patients
November 2022
Published first clinical outcomes study in Genetics in Medicine showing high accuracy of single-gene NIPT
December 2022
Announced $48.5M additional capital raise and $35M upsized term loan facility
January 2023
Northstar Select and Response CLIA launch
January 2023
Northstar Select and Response launched for clinical use
August 2023
BillionToOne Publishes UNITY Fetal RhD and Fetal Antigen NIPT Clinical Validity Demonstrating >99.9% Accuracy
October 2023
BillionToOne Announces Clinical Outcomes Data for UNITY Fetal Risk™ Screen, Demonstrating Exceptional Accuracy in General Pregnancy Population
December 2023
BillionToOne Announces Global Collaboration to Provide its UNITY Fetal Antigen™ Clinical Trial Assay in Johnson & Johnson Phase 3 Clinical Trial of Nipocalimab in Hemolytic Disease of the Fetus and Newborn
April 2024
UNITY Complete helps over 80,000 Pregnant Patients Determine Need for Anti-D Immune Globulin
June 2024
BillionToOne Raises $130 Million in Oversubscribed Series D Funding Over $1B+ Valuation
